Abstract | OBJECTIVES: METHODS: RESULTS: Overall, patients' functioning improved during treatment and follow-up, with significant decreases shortly following PSCT. Shortly after HDM and PSCT, patients reported a considerable increase in levels of soreness in the mouth (+26/+36 points on a scale ranging form 0 to 100; P < 0.01), change of taste (+23/+21 points; P < 0.05/NS), nausea/ vomiting (+26/+27 points; P < 0.01/< 0.05), appetite loss (+40/+43 points; P < 0.001) and diarrhoea (+25/+36 points; P < 0.01). However, none of these symptoms persisted during follow-up. CONCLUSION: The intensive treatment programme was subjectively being well tolerated by the majority of patients. The duration of declined quality of life after administration of HDM seemed to be short. The duration of subjective recovery after PSCT remained uncertain, but in any case was present at the 6 month follow-up. Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma.
|
Authors | C A Uyl-de Groot, I Buijt, I J M Gloudemans, G J Ossenkoppele, H P Berg, P C Huijgens |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 74
Issue 2
Pg. 136-43
(Feb 2005)
ISSN: 0902-4441 [Print] England |
PMID | 15654905
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | (c) Blackwell Munksgaard 2005 |
Chemical References |
|
Topics |
- Adult
- Aged
- Animals
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Female
- Humans
- Male
- Mice
- Middle Aged
- Multiple Myeloma
(therapy)
- Peripheral Blood Stem Cell Transplantation
- Quality of Life
- Surveys and Questionnaires
|